These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33685314)

  • 21. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ultrasound -Induced Thermal Effect Enhances the Efficacy of Chemotherapy and Immunotherapy in Tumor Treatment.
    Xiang Y; Tang L; Pang H; Xu H; He Y; Feng Y; Ju L; Zhang L; Wang D
    Int J Nanomedicine; 2024; 19():6677-6692. PubMed ID: 38975322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing.
    Ngoune R; Contini C; Hoffmann MM; von Elverfeldt D; Winkler K; Putz G
    Curr Drug Deliv; 2018; 15(9):1261-1270. PubMed ID: 29779479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers.
    Yamaguchi K; Matsumoto Y; Suzuki R; Nishida H; Omata D; Inaba H; Kukita A; Tanikawa M; Sone K; Oda K; Osuga Y; Maruyama K; Fujii T
    Cancer Sci; 2021 Jun; 112(6):2493-2503. PubMed ID: 33793049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model.
    Zhang Y; Li A; Wang Z; Han Z; He J; Ma J
    J Drug Target; 2008 Nov; 16(9):679-87. PubMed ID: 18982516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An acoustic/thermo-responsive hybrid system for advanced doxorubicin delivery in tumor treatment.
    Zhang L; Zhang S; Chen H; Liang Y; Zhao B; Luo W; Xiao Q; Li J; Zhu J; Peng C; Zhang Y; Hong Z; Wang Y; Li Y
    Biomater Sci; 2020 Apr; 8(8):2202-2211. PubMed ID: 32100739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
    Gabizon AA; Patil Y; La-Beck NM
    Drug Resist Updat; 2016 Nov; 29():90-106. PubMed ID: 27912846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation and Heat Improve the Delivery and Efficacy of Nanotherapeutics by Modulating Intratumoral Fluid Dynamics.
    Stapleton S; Dunne M; Milosevic M; Tran CW; Gold MJ; Vedadi A; Mckee TD; Ohashi PS; Allen C; Jaffray DA
    ACS Nano; 2018 Aug; 12(8):7583-7600. PubMed ID: 30004666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
    Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
    Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
    Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
    BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
    Yamashita Y; Krauze MT; Kawaguchi T; Noble CO; Drummond DC; Park JW; Bankiewicz KS
    Neuro Oncol; 2007 Jan; 9(1):20-8. PubMed ID: 17018695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy Augmentation Using Low-Intensity Ultrasound Combined with Microbubbles with Different Mechanical Indexes in a Pancreatic Cancer Model.
    Feng S; Qiao W; Tang J; Yu Y; Gao S; Liu Z; Zhu X
    Ultrasound Med Biol; 2021 Nov; 47(11):3221-3230. PubMed ID: 34362582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin.
    de Smet M; Hijnen NM; Langereis S; Elevelt A; Heijman E; Dubois L; Lambin P; Grüll H
    Invest Radiol; 2013 Jun; 48(6):395-405. PubMed ID: 23399809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
    Gibson JM; Alzghari S; Ahn C; Trantham H; La-Beck NM
    Oncologist; 2013; 18(9):1022-31. PubMed ID: 23881990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin.
    Fite BZ; Kheirolomoom A; Foiret JL; Seo JW; Mahakian LM; Ingham ES; Tam SM; Borowsky AD; Curry FE; Ferrara KW
    J Control Release; 2017 Jun; 256():203-213. PubMed ID: 28395970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulsed-wave Ultrasound Hyperthermia Enhanced Nanodrug Delivery Combined with Chloroquine Exerts Effective Antitumor Response and Postpones Recurrence.
    Chiang CF; Hsu YH; Liu CC; Liang PC; Miaw SC; Lin WL
    Sci Rep; 2019 Aug; 9(1):12448. PubMed ID: 31462676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.